Quick Answer
NAC Respiratory Randomized Trial has evidence relevant to benefits, uncertainty, and practical interpretation, but conclusions should stay close to the cited sources. One representative finding is: Results Patients treated with NAC nano-spray demonstrated a significant reduction in WHO mucositis grades and significantly improved OHIP-14 scores compared with the control group (p Conclusions N-acetylcysteine nano-spray appears to be an effective therapeutic option for the management of RIOM, reducing mucositis severity and improving quality of life in oral cancer patients.
Key Takeaways
- 01Results Patients treated with NAC nano-spray demonstrated a significant reduction in WHO mucositis grades and significantly improved OHIP-14 scores compared with the control group (p Conclusions N-acetylcysteine nano-spray appears to be an effective therapeutic option for the management of RIOM, reducing mucositis severity and improving quality of life in oral cancer patients. [Essam A (2026)]
- 02Background Radiation-induced oral mucositis (RIOM) is a common and debilitating complication of radiotherapy in oral cancer patients, significantly impairing quality of life and potentially interrupting treatment. [Essam A (2026)]
- 03This study evaluated the therapeutic efficacy of N-acetylcysteine (NAC) nano-spray in managing RIOM, with particular emphasis on mucositis severity, quality of life, and serum gastrin-17 levels. [Essam A (2026)]
- 04Clinically, it is the standard antidote for acetaminophen (APAP) overdose, restoring hepatic glutathione (GSH) and preventing or mitigating drug-induced liver injury and lowering risk of acute liver failure when administered within the ideal time window.It is also approved as a mucolytic in respiratory disease. [Qu Hui-Qi (2026)]
The current Migaku evidence database contains 2 reusable source documents for NAC Respiratory Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation.
- Results Patients treated with NAC nano-spray demonstrated a significant reduction in WHO mucositis grades and significantly improved OHIP-14 scores compared with the control group (p Conclusions N-acetylcysteine nano-spray appears to be an effective therapeutic option for the management of RIOM, reducing mucositis severity and improving quality of life in oral cancer patients. [Essam A (2026); evidence level 2]
- Background Radiation-induced oral mucositis (RIOM) is a common and debilitating complication of radiotherapy in oral cancer patients, significantly impairing quality of life and potentially interrupting treatment. [Essam A (2026); evidence level 2]
- This study evaluated the therapeutic efficacy of N-acetylcysteine (NAC) nano-spray in managing RIOM, with particular emphasis on mucositis severity, quality of life, and serum gastrin-17 levels. [Essam A (2026); evidence level 2]
- Clinically, it is the standard antidote for acetaminophen (APAP) overdose, restoring hepatic glutathione (GSH) and preventing or mitigating drug-induced liver injury and lowering risk of acute liver failure when administered within the ideal time window.It is also approved as a mucolytic in respiratory disease. [Qu Hui-Qi (2026); evidence level 3]
- In this review, these indicators are used only to illustrate the scale and diversification of NAC-related research activity, whereas assessment of therapeutic relevance rests primarily on mechanistic evidence and clinical studies. [Qu Hui-Qi (2026); evidence level 3]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources
- N-acetylcysteine nano-spray versus conventional treatment in the management of radiotherapy-induced oral mucositis in oral cancer patients: a randomized clinical trial.
- Redefining the role of the thiol-based agent N -acetylcysteine in human health and disease and elucidating potential advantages of its amide derivative